// App-Quantinova.ai

e18720 : Characterizing safety and efficacy in ovarian cancer patients with thromboembolism treated with rivaroxaban.

Researchers

Presenter

  • Christine G. Kohn

Principal Investigators

  • Jonathan T. Caranfa

  • Molly Brewer

  • Meghana Singh

  • Craig I. Coleman

  • Olivia S. Costa

Medical Centers

  • University of Connecticut School of Medicine, Farmington, CT

  • Eatern Connecticut Health Network, Manchester, CT

  • University of Connecticut, Farmington, CT

  • University of Connecticut, Hartford, University of Connecticut School of Pharmacy/Hartford Hospital, Hartford, CT

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

  • Cardiovascular (CVS)

  • Oncology (ONC)

  • Genetic Disorder

  • Blood/haematological Diseases

Disease

  • Venous thrombosis

  • Gynaecological cancer

  • Solid malignancies

Biomarkers

  • Catalase

Drug/Treatment

  • rivaroxaban

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved